Absence of tumor growth stimulation in a panel of 16 human tumor cell lines by mistletoe extracts
Absence of tumor growth stimulation in a panel of 16 human tumor cell lines by mistletoe extracts. By G. Maier and H.H. Fiebig
Published on 1/21/2002
Summary: The results show no evidence of stimulation of tumor growth by any of the three Iscador® preparations, comprising central nervous system, gastric, non-small cell lung, mammary, prostate, renal and uterine cancer cell lines, as well as cell lines from hematological malignancies and melanomas.
|
Changes in Immunological Characteristics of White Blood Cells After ...
Changes in Immunological Characteristics of White Blood Cells after Administration of Standardized Mistletoe Extract. By R. Klopp, W. Schmidt, W. Niemer, M. Werner, J. Beuth
Category: Cancer and Iscador
Published by in vivo 15, 2001 on 8/13/2001
Summary: After administering standardized mistletoe extract, Iscador®, the investigations showed a temporarily improved function of the microcirculation and an increased adhesion and transmigration of white blood cells in the target tissue areas. (article in 3 parts)
|
Changes in Immunological Characteristics of White Blood Cells after ... Part II
Changes in Immunological Characteristics of White Blood Cells after Administration of Standardized Mistletoe Treatment Part II. By R. Klopp, W. Schmidt, W. Niemer, M. Werner, J. Beuth
Category: Cancer and Iscador
Published by in vivo 15, 2001 on 8/13/2001
Summary: After administering standardized mistletoe extract, Iscador®, the investigations showed a temporarily improved function of the microcirculation and an increased adhesion and transmigration of white blood cells in the target tissue areas. (article in 3 parts)
|
Changes in Immunological Characteristics of White Blood Cells after ... Part III
Changes in Immunological Characteristics of White Blood Cells after Administration of Standardized Mistletoe Extract Part III. By R. Klopp, W. Schmidt, W. Niemer, M. Werner, J. Beuth
Category: Cancer and Iscador
Published by in vivo 15, 2001 on 8/13/2001
Summary: After administering standardized mistletoe extract, Iscador®, the investigations showed a temporarily improved function of the microcirculation and an increased adhesion and transmigration of white blood cells in the target tissue areas. (article in 3 parts)
|
Long-term Adjuvant Treatment of Primary Intermediate to High-Risk Malignant Melanoma
Long-term Adjuvant Treatment of Primary Intermediate to High-Risk Malignant Melanoma. By Matthias Augustin et al.
Category: Cancer and Iscador
Published by Arzneim.-Forsch./Drug Research on 1/1/2005
Summary: A long-term Iscador treatment in patients with mean- to high-risk primary malignant melanoma appears to be safe. A tumor enhancement was not observed. In comparison with an untreated parallel control group from the same cohort the results of the mistletoe treatment show a significant survival advantage in the UICC-/AJCC stages II-III.
|
Mistletoe Complementary Treatment in Patients with Primary Non-metastatic Breast Cancer
Mistletoe Complementary Treatment in Patients with Primary Non-metastatic Breast Cancer. By Paul R. Bock et al.
Category: Cancer and Iscador
Published by `Arzneim.-Forsch./Drug Research' on 10/1/2004
Summary: The results of the present study confirmed the safety of the complementary therapy for patients with primary, non-metastatic mammary carcinoma with Iscador ® and showed considerably fewer ADRs attributed to concurrent conventional therapy, as well as reduced disease and treatment-associated symptoms, and suggested a prolonged overall survival in the Iscador ® group as compared with controls.
|
Mistletoe for Pancreatic Cancer Treatment
|
Mistletoe improves tolerability of breast cancer treatment
Mistletoe improves tolerability of breast cancer treatment. By Nancy Walsh
Published by FAMILY PRACTICE NEWS on 2/1/2003
Summary: Multicenter Cohort Study. Adjuvant treatment with mistletoe extract can increase the tolerability of conventional cancer treatment, improve patient quality of life, and lengthen tumor free survival, Dr. Paul R. Bock reported.
|
Study of Mistletoe Treatment for Colorectal Cancer
|
Summary of Multicenter Open Labeled Clinical Study in Advanced Breast Cancer Patients
In an open multicenter study(1) involving 9 oncological centers in Egypt, the effect of Viscum fraxini 2®(2)
was investigated in 26 breast cancer patients with advanced illness.
The study was conducted by Mahfouz et al. in collaboration with H.
Werner, A. Scheffler of the Carl Gustav Carus Institut and I.
Abouleuísh of Atos Pharmaceuticals (Sekem), Cairo.
|
Supportive Care in Pancreatic Carcinoma UICC Stages I-IV Patients treated with Iscador
|
Treatment of Cancer with Iscar® - 160 Frequently Asked Questions and Answers
|
Treatment with Iscador, Patients with Primary Non-Metastatic Colorectal Carcinoma
|
Use of Iscador®, an Extract of European Mistletoe (Viscum Album), in Cancer Treatment
Use of Iscador®, an Extract of European Mistletoe (Viscum Album), in Cancer Treatment. By R. G.-Maticek, Prof Dr med, H. Kiene, Dr med, S. M. Baumgartner, Dr sc nat, R. Ziegler, Dr rer nat
Category: Cancer and Iscador
Published by Alternative Therapies, May/June, Vol. 7, no.3 on 5/1/2001
Summary: A major 30-year-long study with more than 35,000 participants reports that extract of mistletoe (Iscador®) greatly improves survival rate for a wide variety of cancers, including breast cancer. Study participants who augmented conventional therapy with mistletoe extract survived 40% longer compared with those who didn’t use the plant therapy.
|